Fortis Health.Q1 FY27
Fortis Health. Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹911P/E: 64.2Market Cap: ₹68.5K CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →Agilus Diagnostics targets double-digit revenue growth of around 12%-13% going forward, driven by new leadership and strengthened ground teams.
- →The diagnostics business aims to improve operating EBITDA margins to 24%-25%.
- →Growth in the oncology division has moderated to about 10%-12% in volume terms, down from earlier 23%-24%, mainly due to chemo drug pricing pressures, but future growth is expected via radiation and surgical oncology expansion.
- →Hospital occupancy is improving with expectations to increase by 2-3 percentage points as clinical talent and marketing efforts strengthen.
- →Expansion plans include operationalizing 400 additional beds in the current year, especially at flagship FMRI, supporting revenue growth.
- →The preventive diagnostic portfolio contribution is increasing from 12% to 14%, and specialized portfolio from 34% to 35%, indicating a shift to higher-value tests generating better realizations.
- →Focus remains on existing clusters with inorganic growth opportunities under consideration to sustain long-term growth.
Margin guidance
Category 3- →Fortis Healthcare expects hospital EBITDA margin to reach 25% by FY '28, including ESOP costs, driven by brownfield expansions and operational efficiencies.
- →Diagnostic business revenue is projected to grow at 12%-13% with an EBITDA margin maintained around 24%-25%.
- →Oncology growth will moderate to approximately 10%-12%, down from earlier highs due to chemotherapy pricing changes, but volume growth and comprehensive oncology care remain growth drivers.
- →Occupancy levels expected to improve by 2%-3 percentage points, supporting revenue and margin uplift.
- →ESOP costs will impact near-term profitability but are expected to be offset by improved operating performance and talent retention.
- →Capex largely directed to bed expansions (around 400 beds expected operationalized this year) and technical enhancements like proton therapy and robotic surgery to fuel growth.
- →Organic and inorganic growth both pursued, with the latter focused on core clusters but details pending completion.
- →Overall, steady revenue and margin growth driven by volume, specialization, and efficiency are expected over next 2 years.
3 more insights locked — sign up free to unlock
Fundraise plans
- →Fortis Healthcare is currently investing heavily in growth, including a 2,000-bed expansion, primarily funded by internal cash flows.
- →Around 50% of EBITDA is being consumed for brownfield expansion without acquisitions.
- →The company is actively pursuing inorganic growth deals but has not disclosed specifics since deals are not yet concluded.
- →No explicit mention of planned fundraising through new debt or equity in the near term.
- →Net debt increased primarily due to prior year acquisitions, standing at INR 2,233 crores with a net debt/EBITDA ratio of 1.01x as of June 30, 2026.
- →Management emphasizes focus on funding growth through operations and selective acquisitions within existing clusters.
- →For now, no concrete plans for additional debt or equity raising have been announced; future inorganic moves are subject to deal closures.
Order book
The transcript does not explicitly mention details about the current or expected order book or pending orders for Fortis Healthcare Limited. However, relevant points related to growth and expansion include:
- The company is actively pursuing inorganic deals, particularly in focus clusters, but details are yet to be concluded.
- Fortis Healthcare is expanding its network with a 2,000-bed brownfield expansion underway, indicating ongoing capacity enhancement.
- New customer touch points in diagnostics have increased to 4,493 as of June 30, 2026, supporting network growth.
- An O&M agreement for a 300-bed greenfield hospital in Cuttack has been entered, marking entry into Odisha.
- The company is focusing on ramping up occupancy in existing and new units, with plans to operationalize 400 more beds within the year.
- Active evaluation and expected conclusion of growth opportunities in existing clusters are ongoing.
No specific figures for orderbook or pending orders were disclosed.
Capex plans
Yes- →The company plans a 2,000-bed expansion, with around 50% of EBITDA being consumed by this brownfield growth (Page 14).
- →Specific Capex for Proton Therapy in Delhi NCR is under finalization, estimated around INR 252 crores (Page 13).
- →Bed expansion is ongoing, with 100 beds operationalized in Q1 and another 400 beds expected to come online in the remaining quarters, including 200 beds at the FMRI flagship hospital (Page 12).
- →Radiation oncology equipment installation at Manesar to be completed by November, enabling a comprehensive oncology center (Page 8).
- →The company is also investing in technical capabilities like proton therapy, robotic surgery, and new cancer care units (Page 14).
- →Inorganic acquisitions are under active pursuit but details are pending until deals conclude (Page 14).
- →O&M project in Odisha is a low-capital commitment move; focus remains on existing clusters for capital deployment (Page 9).
How does Fortis Health. rank vs peers in Healthcare Services?
Pro feature1Fortis Health.
Rev 3Mar 3
See full Healthcare Services sector rankings
How does Fortis Health. rank in Healthcare Services?
Compare Fortis Health. against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.